UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies

Clinical and experimental immunology, 2017-01, Vol.187 (1), p.146-159

2017

Volltextzugriff (PDF)

P252 Results of a phase 2/3 study of SCIG 20% in PIDD patients in North America

Annals of allergy, asthma, & immunology, 2016-11, Vol.117 (5), p.S97-S97

2016

Volltextzugriff (PDF)

P254 Local adverse reactions decreased over time during IGHY treatment in patients with PIDD

Annals of allergy, asthma, & immunology, 2016-11, Vol.117 (5), p.S97-S98

2016

Volltextzugriff (PDF)

P253 Safety and tolerability of SCIG 20% in patients with PIDD in europe and north america

Annals of allergy, asthma, & immunology, 2016-11, Vol.117 (5), p.S97-S97

2016

Volltextzugriff (PDF)

Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies

Clinical and experimental immunology, 2008-05, Vol.152 (2), p.274-279

2008

Volltextzugriff (PDF)

Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients With Primary Immunodeficiency Disease (PIDD)

Journal of allergy and clinical immunology, 2012-02, Vol.129 (2), p.AB203-AB203

2012

Volltextzugriff (PDF)

Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD)

Journal of allergy and clinical immunology, 2012-02, Vol.129 (2), p.AB15-AB15

2012

Volltextzugriff (PDF)

Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency Disease (PIDD)

Journal of allergy and clinical immunology, 2012-02, Vol.129 (2), p.AB14-AB14

2012

Volltextzugriff (PDF)

Pharmacokinetics (PK) of Human Immunoglobulin 10% Administered Subcutaneously Alone or Following Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB213-AB213

2011

Volltextzugriff (PDF)

Efficacy Analysis of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD)

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB15-AB15

2011

Volltextzugriff (PDF)

Tolerability of Human Immunoglobulin 10% Administered Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB15-AB15

2011

Volltextzugriff (PDF)

New Immune Globulin Subcutaneous (Human), 10% (IGSC) Product is Well Tolerated in Subjects with Primary Immunodeficiency Diseases (PIDD)

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB16-AB16

2011

Volltextzugriff (PDF)

Pharmacokinetic Analysis (PK) of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD)

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB17-AB17

2011

Volltextzugriff (PDF)

Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia

Vox sanguinis, 2006-05, Vol.90 (4), p.286-293

2006

Volltextzugriff (PDF)

IGIV-10% Infused Intravenously And Subcutaneously To Subjects With Primary Immunodeficiency Diseases - Comparison Of Pharmacokinetic Properties

Journal of allergy and clinical immunology, 2009-02, Vol.123 (2), p.S11-S11

2009

Volltextzugriff (PDF)

Recombinant Human Hyaluronidase Facilitates Dispersion of Subcutaneously Administered Gammagard Liquid and Enables Administration of a Full Monthly Dose in a Single Site to Patients with Immunodeficiency Diseases

Journal of allergy and clinical immunology, 2008-02, Vol.121 (2), p.S83-S83

2008

Volltextzugriff (PDF)

P279 Post-authorization safety study of hyaluronidase-facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases

Annals of allergy, asthma, & immunology, 2017-11, Vol.119 (5), p.S71-S71

2017

Volltextzugriff (PDF)

Innocuité et tolérabilité de l’immunoglobuline humaine G à 20 %, administrée par voie sous-cutanée (Ig20Gly) : analyse finale d’une étude de phase 2/3 portant sur des patients souffrant de déficits immunitaires primitifs (DIP) en Europe

La revue de medecine interne, 2018-12, Vol.39, p.A188-A188

2018

Volltextzugriff (PDF)

Sécurité d’emploi, efficacité et tolérance à long terme de la perfusion sous-cutanée d’immunoglobulines G facilitée par la hyaluronidase humaine recombinante chez des enfants et des adultes atteints de déficit immunitaire primitif (DIP)

La revue de medecine interne, 2017-06, Vol.38, p.A172-A172

2017

Volltextzugriff (PDF)

Efficacy, safety and tolerability of a new intravenous immune globulin, 10% liquid, triple virus reduced (IGIV,10%TVR) in patients with primary immunodeficiency (PID)

Journal of allergy and clinical immunology, 2005-02, Vol.115 (2), p.S160-S160

2005

Volltextzugriff (PDF)

Tetanus antibody levels of female volunteers after injection with solvent/detergent-treated human tetanus immunoglobulin (Tetabulin S/D)

Vox sanguinis, 2001-04, Vol.80 (3), p.159-161

2001

Volltextzugriff (PDF)

Efficacy, Safety, and Tolerability of Intravenous Gammaglobulin (IGIV, 10%) in a Phase 3, Randomized, Placebo-Controlled, Cross-Over Trial for the Treatment of Multifocal Motor Neuropathy (MMN) (PL02.002)

Neurology, 2012-04, Vol.78 (Meeting Abstracts 1), p.PL02.002-PL02.002

2012

Volltextzugriff (PDF)

Expression of Thy-1 Antigen by Murine Epidermal Cells

Journal of investigative dermatology, 1983-09, Vol.81 (3), p.282-285

1983

Volltextzugriff (PDF)

Affinity Binding of Distinct Functional Fibronectin Domains to Immobilized Metal Chelates

Archives of biochemistry and biophysics, 1995-08, Vol.321 (1), p.40-42

1995

Volltextzugriff (PDF)

Isolation of Human Serum IgA Using Thiophilic Adsorption Chromatography

Protein expression and purification, 1995-08, Vol.6 (4), p.408-410

1995

Volltextzugriff (PDF)

1 – 25 von 135

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(121)
Mit Volltextzugriff
(111)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(63)
Life Sciences & Biomedicine
(59)
Humans
(51)
Biological And Medical Sciences
(39)
Female
(33)
Male
(22)
Fundamental And Applied Biological Sciences. Psychology
(20)
Medical Sciences
(20)
Middle Aged
(17)
Animals
(16)
Adult
(15)
Biochemistry & Molecular Biology
(15)
Aged
(14)
Allergy And Immunology
(13)
Biophysics
(12)
Immunology
(9)
Kinetics
(9)
Photosynthesis
(9)
Cell Structures And Functions
(8)
Chloroplast, Photosynthetic Membrane And Photosynthesis
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies

P252 Results of a phase 2/3 study of SCIG 20% in PIDD patients in North America

P254 Local adverse reactions decreased over time during IGHY treatment in patients with PIDD

P253 Safety and tolerability of SCIG 20% in patients with PIDD in europe and north america

Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies

Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients With Primary Immunodeficiency Disease (PIDD)

Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD)

Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency Disease (PIDD)

Pharmacokinetics (PK) of Human Immunoglobulin 10% Administered Subcutaneously Alone or Following Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients

Efficacy Analysis of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD)

Tolerability of Human Immunoglobulin 10% Administered Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients

New Immune Globulin Subcutaneous (Human), 10% (IGSC) Product is Well Tolerated in Subjects with Primary Immunodeficiency Diseases (PIDD)

Pharmacokinetic Analysis (PK) of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD)

Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia

IGIV-10% Infused Intravenously And Subcutaneously To Subjects With Primary Immunodeficiency Diseases - Comparison Of Pharmacokinetic Properties

Recombinant Human Hyaluronidase Facilitates Dispersion of Subcutaneously Administered Gammagard Liquid and Enables Administration of a Full Monthly Dose in a Single Site to Patients with Immunodeficiency Diseases

P279 Post-authorization safety study of hyaluronidase-facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases

Innocuité et tolérabilité de l’immunoglobuline humaine G à 20 %, administrée par voie sous-cutanée (Ig20Gly) : analyse finale d’une étude de phase 2/3 portant sur des patients souffrant de déficits immunitaires primitifs (DIP) en Europe

Sécurité d’emploi, efficacité et tolérance à long terme de la perfusion sous-cutanée d’immunoglobulines G facilitée par la hyaluronidase humaine recombinante chez des enfants et des adultes atteints de déficit immunitaire primitif (DIP)

Efficacy, safety and tolerability of a new intravenous immune globulin, 10% liquid, triple virus reduced (IGIV,10%TVR) in patients with primary immunodeficiency (PID)

Tetanus antibody levels of female volunteers after injection with solvent/detergent-treated human tetanus immunoglobulin (Tetabulin S/D)

Efficacy, Safety, and Tolerability of Intravenous Gammaglobulin (IGIV, 10%) in a Phase 3, Randomized, Placebo-Controlled, Cross-Over Trial for the Treatment of Multifocal Motor Neuropathy (MMN) (PL02.002)

Expression of Thy-1 Antigen by Murine Epidermal Cells

Affinity Binding of Distinct Functional Fibronectin Domains to Immobilized Metal Chelates

Isolation of Human Serum IgA Using Thiophilic Adsorption Chromatography

Suchergebnisse filtern